ClinicalTrials.gg

Program

JZP441

A development code.

Its studies are mostly in Narcolepsy, led by Jazz Pharmaceuticals.

Furthest: phase 1, since Nov 28, 20223 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals30 open or runningphase 1since Nov 28, 2022Nov 28, 2022none ahead

Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2022First study: phase 1 study in Healthy ParticipantsFirst studyNCT05651152 · 105 enrolled · United States
  2. Jan 31, 2023Phase 1 study in Healthy ParticipantsNCT05720494 · 24 enrolled · United States
  3. Apr 29, 2025Phase 1 study in NarcolepsyNCT06961266 · 6 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06961266Narcolepsy · United States1TerminatedJan 29, 20266
NCT05720494Healthy Participants · United States1CompletedSep 29, 202324
NCT05651152Healthy Participants · United States1CompletedNov 15, 2023105

How it is read

Names in the registry

  • “JZP441”, 3 entries

Codes read as this program: JZP441.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.